Clinical Trial

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 17, 2023 (before its estimated October 14, 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, open, single-center, single-arm phase II clinical study with common EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory.To evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
Trial Details
NCT Number NCT05686434
Lead Sponsor Tianjin Medical University Cancer Institute and Hospital
Conditions NSCLC, Stage I
Enrollment 65 participants
Start Date 2022-10-14
Primary Completion 2024-10-14 (estimated)
Study Completion 2029-10-14 (estimated)
Updated on ClinicalTrials.gov 2023-01-17